DrugPatentWatch Database Preview

Upjohn Company Profile

« Back to Dashboard

What is the competitive landscape for UPJOHN, and when can generic versions of UPJOHN drugs launch?

UPJOHN has twenty approved drugs.

There are four US patents protecting UPJOHN drugs.

There are one hundred and forty-two patent family members on UPJOHN drugs in fifty-nine countries and thirty-nine supplementary protection certificates in eleven countries.

Summary for Upjohn

International Patents:	142
US Patents:	4
Tradenames:	14
Ingredients:	12
NDAs:	20

Drugs and US Patents for Upjohn

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Upjohn	XANAX XR	alprazolam	TABLET, EXTENDED RELEASE;ORAL	021434-002	Jan 17, 2003	AB	RX	Yes	No
Upjohn	XANAX	alprazolam	TABLET;ORAL	018276-002	Approved Prior to Jan 1, 1982	AB	RX	Yes	No
Upjohn	REVATIO	sildenafil citrate	SOLUTION;INTRAVENOUS	022473-001	Nov 18, 2009	AP	RX	Yes	Yes
Upjohn	GEODON	ziprasidone hydrochloride	CAPSULE;ORAL	020825-002	Feb 5, 2001	AB	RX	Yes	No
Upjohn	XANAX	alprazolam	TABLET;ORAL	018276-004	Nov 27, 1985	AB	RX	Yes	No
Upjohn	EFFEXOR XR	venlafaxine hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	020699-001	Oct 20, 1997	AB	RX	Yes	No

Expired US Patents for Upjohn

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Upjohn	NEURONTIN	gabapentin	CAPSULE;ORAL	020235-002	Dec 30, 1993	4,894,476*PED
Upjohn	EFFEXOR XR	venlafaxine hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	020699-004	Oct 20, 1997	6,419,958*PED
Upjohn	EFFEXOR XR	venlafaxine hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	020699-001	Oct 20, 1997	6,419,958*PED
Upjohn	DETROL	tolterodine tartrate	TABLET;ORAL	020771-002	Mar 25, 1998	5,550,269*PED
Upjohn	VIAGRA	sildenafil citrate	TABLET;ORAL	020895-002	Mar 27, 1998	5,250,534*PED
Upjohn	GEODON	ziprasidone hydrochloride	CAPSULE;ORAL	020825-002	Feb 5, 2001	4,831,031

Paragraph IV (Patent) Challenges for UPJOHN drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
	Extended-release Tablets	37.5 mg, 75 mg and 150 mg		2007-05-03
	Tablets	150 mg and 200 mg		2005-11-09
	Tablets	100 mg		2004-10-25
	Capsules	20 mg, 40 mg, 60 mg and 80 mg		2005-02-07
	Tablets	25 mg and 50 mg		2004-11-19

International Patents for Upjohn Drugs

Country	Patent Number	Estimated Expiration
United Kingdom	9301192
Hong Kong	1062646
Dominican Republic	P2002000403
Tunisia	SN03125
Ecuador	SP941102
South Korea	100417200

Supplementary Protection Certificates for Upjohn Drugs

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1003503	05C0048	France		PRODUCT NAME: AMLODIPINE OU UN DE SES SELS D?ADDITION D?ACIDES PHARMACAUTIQUEMENT ACCEPTABLES/ ATORVASTATINE OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE IN FRANCE: NL 29929 DU 20050707; REGISTRATION NO/DATE AT EEC: NL 29929 DU 20050707
0364417	C970039	Netherlands		PRODUCT NAME: [1R-[1 ALPHA (Z),2 BETA(R*),3 ALPHA,5ALPHA]]-7-[3,5-DIHYDROXY-2-(3-HYDROXY-5- FENYLPENTYL)CYCLOPENTYL]-5-HEPTEENZUUR, DESGEWENST IN DE VORM VAN EEN ZOUT OF EEN ESTER, IN HET BIJZONDER LATANOPROSTUM; NAT. REGISTRATION NO/DATE: RVG 21304 19970610; FIRST REGISTRATION: SE 12716 19960718
0443983	C00443983/03	Switzerland		PRODUCT NAME: VALSARTAN + AMLODIPINE + HYDROCHLOROTHIAZIDE; REGISTRATION NUMBER/DATE: SWISSMEDIC 59407 16.09.2009
0247633	C970034	Netherlands		PRODUCT NAME: ATORVASTATINUM,DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT OF VAN HET INWENDIGE DELTA-LACTON, IN HET BIJZONDER ATORVASTATINUM CALCICUM TRIHYDRICUM; NAT. REGISTRATION NO/DATE: RVG 21081 - RVG 21083 19970421; FIRST REGISTRATION: GB PL 00018/0240 - PL 00018/0242 19961107
0720599	300689	Netherlands		PRODUCT NAME: EZETIMIBE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, EN ATORVASTATINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER ATORVASTATINE CALCIUM TRIHYDRATE; NATIONAL REGISTRATION NO/DATE: RVG114373-114376 20141027; FIRST REGISTRATION: FR 2014091200122 20140912
0502314	SPC/GB11/010	United Kingdom		PRODUCT NAME: THE COMBINATION OF A) TELMISARTAN, OPTIONALLY IN THE FORM OF PHARMACEUTICALLY ACCEPTABLE SALTS, AND B) AMLODIPINE, OPTIONALLY IN THE FORM OF PHARMACEUTICALLY ACCEPTABLE SALTS, ESPECIALLY AMLODIPINE BESYLATE; REGISTERED: UK EU/1/10/648/001 20101007; UK EU/1/10/648/002 20101007; UK EU/1/10/648/003 20101007; UK EU/1/10/648/004 20101007; UK EU/1/10/648/005 20101007; UK EU/1/10/648/006 20101007; UK EU/1/10/648/007 20101007; UK EU/1/10/648/008 20101007; UK EU/1/10/648/009 20101007; UK EU/1/10/648/010 20101007; UK EU/1/10/648/011 20101007; UK EU/1/10/648/012 20101007; UK EU/1/10/648/013 20101007; UK EU/1/10/648/014 20101007; UK EU/1/10/648/015 20101007; UK EU/1/10/648/016 20101007; UK

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Upjohn